DrChrono
Winter 2011AcquiredThe essential platform for modern medical practices and patients.
Pressure-test this opportunity
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
The essential platform for modern medical practices and patients.
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
DrChrono used the iPad to bring electronic health records into the patient encounter, then expanded into software for running an independent medical practice. Founded in 2009 by Michael Nusimow and Daniel Kivatinos, the Winter 2011 YC company eventually connected charting, scheduling, billing, patient communication, and partner applications.[21]
EverCommerce acquired all of DrChrono on November 18, 2021, for $181.9 million in cash consideration. Its purchase joined a clinical system of record to an existing healthcare software portfolio. DrChrono continues as an EverHealth brand, with current products, support instructions, and operational maintenance notices.[2][16] The useful lesson is how a focused interface became a distribution point for a broader practice workflow.
Image 1 / 1
Nusimow and Kivatinos founded DrChrono in 2009. YC's January 2012 profile identifies Nusimow as co-founder and chief executive. He explained the product's starting point: “Doctors are beginning to adopt iPads and use them as clipboards.” The same profile describes his concern that typing during a visit distracted clinicians from patients.[1][3]
That gave the device choice a purpose. A portable chart could stay with the clinician during the encounter. Mobile input mattered because the medical record had to be completed while attention remained on the patient. The subsequent expansion into billing and scheduling addressed the administrative work surrounding that encounter.
The company announced $2.8 million in financing in January 2012, following an earlier $1.3 million from investors including YC, Paul Buchheit, and 500 Startups. YC reproduced this account from the New York Times.[3]
By June 2021, Kivatinos described the expanded company to MobiHealthNews: “Really, the core of the company is a platform that has several modules.” Those modules covered medical records, practice management, and billing. He also described allowing telehealth partners to connect before DrChrono launched its own telehealth experience.[8] This was a progression from controlling the interface to coordinating the surrounding services.
DrChrono's product connected the steps around a medical visit. Staff could schedule the patient and collect intake information. Clinicians could document the encounter on mobile devices. Billing staff could turn the record into claims, track payment, and manage patient balances. The acquisition announcement described an integrated cloud EHR, practice-management, and billing product for independent practices.[4]
The company also let partners extend that workflow. Its March 2019 CoverMyMeds announcement describes prescription-price information and electronic prior authorization at prescribing. Its July 2019 DeepScribe announcement describes recording an encounter with patient permission, preparing notes, and returning them for provider review and signature. These are vendor-described workflows, rather than independent measurements of accuracy or clinical benefit.[10][11]
IntelliH added another connection in October 2021. DrChrono's announcement describes collecting patient vitals and remote-monitoring reports in the medical chart. The integration supplied implementation and support services alongside software. Its claimed clinical and revenue benefits were not supported by a controlled comparison in the announcement.[12]
The partner model also provided distribution. The current partner page offers API access, a marketplace listing, and co-marketing opportunities. Developers could reach practices already using the EHR; practices could add functions without replacing their record system.[13] This reduces the number of vendors DrChrono must build internally, while adding responsibility for access, identity matching, and integration maintenance.
DrChrono targets independent practices, from solo clinicians to multi-location groups. Its current site places clinical records, practice administration, and patient engagement in the same offering.[1] Those customers must coordinate several jobs with a smaller administrative team than a hospital system.
EverCommerce reported more than 4,600 independent practices and 13,000 providers at the November 2021 acquisition.[4] In 2012, DrChrono reported 15,000 registered providers and 400,000 patients.[22] These company and acquirer figures are not an audited estimate of the addressable market. Earlier registered-provider counts use a different definition and do not establish growth or decline against this figure.
DrChrono's January 2020 announcement reported 17.8 million patients under its providers' care, 69 million appointments booked, and more than $11 billion in medical billing processed to date.[5] The billing figure measures activity through the platform, not DrChrono revenue. These cumulative figures establish workflow scale more clearly than they establish company economics.
Current competition includes athenaOne, which offers practice and revenue-cycle workflows plus authorization management. Its official product page describes authorization determination, tracking, payer requirements, and a managed-service option.[18] This overlaps administrative work DrChrono and its partners already support; mobile software alone no longer defines a separate category.
Within DrChrono, CoverMyMeds also covers an important proposed rebuild function. A September 2026 support article explains receiving pharmacy requests, validating patient and prescriber matches, completing questions, and receiving payer responses inside DrChrono.[15] A new authorization product would need to prove an unmet preparation job inside this existing workflow. It cannot assume that practices lack electronic authorization tools.
DrChrono sells practice software and revenue-cycle services. Its current pricing page offers Foundation, Growth, and Premium plans by quote. The comparison distinguishes billing tools, revenue-cycle software, and advanced add-ons. It also lists usage-based charges and payment-processing fees.[14] These are present-day terms, not evidence of the company's 2021 prices or revenue mix.
The ORIX financing illustrates why capital labels matter. DrChrono called its January 2020 round $20 million of growth capital, while ORIX called the investment debt. The announcement identified engineering, sales, support, EHR, billing, and API expansion as uses.[5][6] Debt financing alone does not demonstrate distress, and describing all this capital as venture equity would misstate the financing path.
The public sources here do not establish standalone revenue, margins, retention, acquisition cost, or investor proceeds. EverCommerce's acquisition accounting records $181.9 million of consideration. Its earlier approximately $182.5 million estimate belonged to the pending transaction; the amounts should not be treated as two separate deals.[2][9]
The customer counts documented a substantial independent-practice footprint by acquisition. They do not show how many accounts were profitable or how often clinicians used each module. Kivatinos's June 2021 interview also reported approximately 400,000 appointments per week and 100,000 appointments reached by DrChrono's own telehealth product. These were founder-reported activity measures.[8]
Current operation is supported by more than a retained logo. DrChrono maintains a detailed support center and a status page that recorded September 2026 maintenance. Its October 2025 integration notice instructed partners to move application traffic away from the public website domain, with rejection starting in November and support ending in December.[16][17] This shows continuing operational work; it does not establish uptime, customer satisfaction, or post-acquisition growth.
EverCommerce's November 2021 filing excerpt states that it expected DrChrono to connect with existing and adjacent EverHealth products and extend mobile capabilities. It specifically describes an “opportunity for payments integration.”[9] The completed-acquisition release describes DrChrono as a central product for independent practices.[4]
The mechanism is concrete. A practice already uses the clinical record to identify a patient and document an encounter. Scheduling, communication, billing, and payment can follow that same encounter. EverHealth now includes CollaborateMD and Updox alongside DrChrono.[1] A buyer with adjacent products can sell through that established relationship instead of acquiring the practice separately for every service. That is an interpretation of the buyer's stated integration strategy, not evidence that expected cross-sales or cost savings occurred.
DrChrono's partner history supports this explanation. CoverMyMeds and DeepScribe inserted their work into the record before the acquisition. The current partner program still offers marketplace distribution.[10][11][13] The company's usefulness as a connection point had value beyond its original mobile interface.
DrChrono had financed expansion, built partner integrations, and reached thousands of practices. These facts also support a plausible independent growth path. The sale documents do not disclose the board's alternatives or prove that DrChrono needed rescue. Without standalone economics and shareholder terms, the purchase price cannot establish whether independence would have produced a better return.
Acquisition therefore explains a change of ownership, rather than a shutdown. The strongest supported thesis is strategic fit between the practice workflow and EverCommerce's portfolio. Continued product support establishes that the workflow survived; it does not validate every acquisition promise.
The same shared workflow can spread an error. A wrong patient match, stale payer criterion, or unsupported note can affect a prescription request or billing packet. DrChrono's current authorization documentation explicitly checks medication, prescriber, patient, and duplicate-request matches.[15] These checks explain why administrative automation needs visible sources and clear responsibility.
Owning an EHR does not establish that every partner feature is clinically validated or compliant in every deployment. Product claims, certification scope, authorized access, and clinical judgment require separate evidence. A rebuild should collect traceable facts and block missing prerequisites before it asks a reviewer to approve a packet.